Segall Bryant & Hamill LLC Buys Shares of 289,075 Denali Therapeutics Inc. (NASDAQ:DNLI)

Segall Bryant & Hamill LLC purchased a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 289,075 shares of the company’s stock, valued at approximately $5,891,000.

Several other hedge funds and other institutional investors have also made changes to their positions in DNLI. Quest Partners LLC acquired a new position in Denali Therapeutics in the third quarter valued at about $73,000. PNC Financial Services Group Inc. increased its stake in shares of Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock valued at $77,000 after acquiring an additional 885 shares during the last quarter. KBC Group NV raised its position in shares of Denali Therapeutics by 75.8% in the 4th quarter. KBC Group NV now owns 6,334 shares of the company’s stock valued at $129,000 after acquiring an additional 2,731 shares during the period. AlphaQuest LLC boosted its stake in Denali Therapeutics by 177.1% during the 4th quarter. AlphaQuest LLC now owns 6,961 shares of the company’s stock worth $142,000 after acquiring an additional 4,449 shares during the last quarter. Finally, E Fund Management Co. Ltd. grew its holdings in Denali Therapeutics by 32.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company’s stock valued at $204,000 after purchasing an additional 2,436 shares during the period. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Trading Down 2.2 %

Denali Therapeutics stock opened at $13.81 on Thursday. Denali Therapeutics Inc. has a 1-year low of $13.67 and a 1-year high of $33.33. The company has a fifty day simple moving average of $19.34 and a 200 day simple moving average of $23.39. The company has a market cap of $2.01 billion, a P/E ratio of -5.00 and a beta of 1.46.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.08. On average, equities research analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Analyst Ratings Changes

DNLI has been the topic of several analyst reports. Bank of America cut their target price on shares of Denali Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, March 10th. B. Riley reaffirmed a “buy” rating and set a $35.00 price objective (down previously from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. Morgan Stanley assumed coverage on Denali Therapeutics in a research note on Friday, March 7th. They issued an “overweight” rating and a $33.00 target price for the company. JPMorgan Chase & Co. dropped their price target on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 7th. Finally, HC Wainwright boosted their price objective on Denali Therapeutics from $80.00 to $87.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $37.20.

Insiders Place Their Bets

In other news, Director Vicki L. Sato sold 3,080 shares of Denali Therapeutics stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the transaction, the director now owns 107,976 shares of the company’s stock, valued at $2,257,778.16. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Steve E. Krognes sold 3,339 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the completion of the sale, the director now directly owns 25,757 shares in the company, valued at approximately $536,003.17. The trade was a 11.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,940 shares of company stock valued at $973,442 in the last 90 days. 7.90% of the stock is currently owned by insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.